CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024 Company anticipates initial human trials to focus on AML upon IND clearance SOUTH SAN FRANCISCO, Calif., July 08, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO)...

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236 Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO)...

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) --  CERo...

CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of...